6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00442780 (ClinicalTrials.gov)	August 2007	1/3/2007	Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's Disease	Parkinson's Disease	Drug: BIIB014;Drug: Placebo	Biogen Idec	NULL	Completed	30 Years	N/A	Both	36	Phase 2	Israel;Poland;Serbia;Former Serbia and Montenegro
2	NCT00438607 (ClinicalTrials.gov)	April 2007	20/2/2007	Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects With Moderate to Late Stage Parkinson's Disease Who Are Also Receiving Treatment With Levodopa	Parkinson's Disease	Drug: BIIB014;Drug: Placebo	Biogen Idec	NULL	Completed	30 Years	N/A	Both	83	Phase 2	India;Israel;United Kingdom
3	EUCTR2006-003490-27-GB (EUCTR)	19/12/2006	29/09/2006	A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with Levodopa	A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with Levodopa	Parkinson's disease MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease	Product Code: BIIB014 Product Code: BIIB014 Product Code: BIIB014	BIOGEN IDEC LTD	NULL	Not Recruiting			Female: yes Male: yes	137	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
4	NCT00451815 (ClinicalTrials.gov)	January 2003	31/1/2006	BIIB014 Phase 2a Monotherapy	A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson’s Disease	Parkinson's Disease	Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;Drug: placebo	Biogen Idec	NULL	Withdrawn	30 Years	78 Years	Both		Phase 2	NULL